## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 4.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Edwards Lifesciences (NYSE: EW) targets 2026 EPS of $2.80-$2.95 with TMTT up 35%-45%**
- Source: Stock Titan | 20251204T140813 | Bullish | Relevance: 99%
-  Edwards Lifesciences outlined its patient-focused strategy and financial guidance, projecting 2026 constant currency sales growth of 8%-10% to $6.4-$6.8 billion and adjusted EPS of $2.80-$2.95. The company expects significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, targeting 35%-45% constant currency growth. Edwards is focusing on advancing structural heart therapies, including TAVR, TMTT, surgical innovations, and pioneering new areas like Structural Heart Failure and TAVR-AR.

**2. Edwards Lifesciences stock maintains Neutral rating at UBS ahead of Investor Day By Investing.com**
- Source: Investing.com | 20251203T100600 | Somewhat-Bullish | Relevance: 99%
- UBS has maintained its Neutral rating and $90.00 price target for Edwards Lifesciences ahead of the company's Investor Day, noting the stock trades closely to its Fair Value. The decision follows improved long-term TAVR data and strong stock performance, with UBS anticipating 2026 guidance to align with investor expectations for high-single-digit global TAVR sales growth. Other firms like Bernstein, Canaccord Genuity, Raymond James, and Piper Sandler have also reacted to recent positive financial results, with several raising their price targets.

**3. OMERS ADMINISTRATION Corp Boosts Stock Holdings in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251203T124745 | Somewhat-Bullish | Relevance: 99%
- OMERS ADMINISTRATION Corp significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 97.3%, acquiring an additional 21,950 shares. This boosted their total holdings to 44,504 shares valued at $3.48 million, contributing to institutional investors owning 79.46% of the stock. Meanwhile, company insiders have recently been selling shares, with the VP selling 1,020 shares and the CFO selling 13,000 shares.

**4. Edwards Lifesciences stock hits 52-week high at 87.42 USD**
- Source: Investing.com | 20251205T153914 | Bullish | Relevance: 99%
-  Edwards Lifesciences (EW) stock reached a new 52-week high of $87.42, marking an 18.43% increase over the past year and reflecting strong investor confidence. Despite a P/E ratio suggesting it might be slightly overvalued, the company maintains a "GOOD" financial health rating and aggressive share buybacks. Analyst price targets have also been raised following the company's annual investor day, indicating a positive outlook for its future performance.

**5. Edwards Lifesciences Sets Cautious Targets Yet Keeps Investors Interested**
- Source: Finimize | 20251205T164027 | Somewhat-Bullish | Relevance: 99%
-  Edwards Lifesciences announced conservative financial targets for 2026, including around 10% annual revenue growth and specific sales goals for transcatheter aortic, mitral, and tricuspid valves. Despite these cautious projections, Wall Street analysts and investors remain optimistic, with RBC Capital Markets raising its price target to $100 due to strong demand for the company's heart therapies and an impressive 78.5% gross margin. This suggests confidence that Edwards Lifesciences (EW) could outperform its own guidance as innovations in structural heart therapies continue to drive growth in a global aging population.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.06M) |
| Sells | 3 ($0.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.13 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.9B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.13 |
| Forward P/E | 30.0 |
| Current P/E | 33.4 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.3% to -1.0% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.96% (CS: 45) | Neutral |
| RSI_14 | 59.1 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.123x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.19
- **Stop Loss:** $82.45 (4.3% risk)
- **Target:** $89.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $11,463.27
- **Portfolio %:** 11.46%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*